Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders

Philadelphia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary duties to the company and its shareholders.

What Is The Investigation About? Grabar Law Office is investigating allegations that ADMA's officers and directors failed to implement and maintain adequate internal controls and oversight mechanisms concerning the Company's revenue recognition practices, related-party transactions, and public disclosures.

If you purchased ADMA Biologics (NASDAQ: ADMA) shares prior to August 9, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost or fee to you whatsoever - ever. Visit https://grabarlaw.com/the-latest/adma-shareholder-investigation/, email Joshua H. Grabar at [email protected], or call us at 267-507-6085.

What Is Alleged? According to recently filed securities fraud class action, ADMA allegedly:

• Failed to disclose certain related-party transactions involving entities allegedly associated with Company insiders;
• Engaged in practices that allegedly inflated reported revenue through channel-stuffing activities;
• Maintained inadequate internal accounting and disclosure controls;
• Made materially misleading statements concerning the effectiveness of internal controls and financial reporting;
• Failed to provide shareholders with accurate information concerning the Company's business operations, revenues, and prospects; and
• Exposed the Company to significant legal, regulatory, reputational, and financial risk.

On March 24, 2026, a research report publicly challenged ADMA's reported growth and alleged that the Company had engaged in channel-stuffing practices and failed to disclose a material related-party distribution relationship. The report further alleged that ADMA's reported revenue growth was materially overstated and that substantial product inventory had accumulated within distribution channels.

What Can You Do Now? If you purchased ADMA Biologics (NASDAQ: ADMA) shares prior to August 9, 2024, and still hold shares today, please visit https://grabarlaw.com/the-latest/adma-shareholder-investigation/, email Joshua H. Grabar at [email protected], or call us at 267-507-6085. You can seek claims on behalf of the Company against officers and directors responsible for alleged corporate wrongdoing, corporate governance reforms designed to protect the Company and its shareholders, and a court approved incentive award at no cost or fee to you whatsoever - ever.

#ADMA $ADMA #ADMABiologics

About Grabar Law Office

Grabar Law Office represents institutional and individual investors in shareholder derivative litigation, securities litigation, and corporate governance matters, as well as antitrust matters, and consumer protection matters throughout the United States. The firm has extensive experience prosecuting claims involving breaches of fiduciary duty, inadequate corporate oversight, misleading disclosures, insider misconduct, and failures of corporate governance.

For additional information concerning this investigation, please contact:

Attorney Advertising Disclaimer

Attorney Advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302043

You May Also Be Interested In

• ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• BofA Securities Upgrades Tesco Plc. (TSCO:LN) (TSCDY) to Buy
• KeyBanc Upgrades Duke Energy (DUK) to Overweight